BUY Akums Drugs and Pharmaceuticals — Citigroup, 18 Aug 2026

byCitigroupHorizon: NA (inferred 1 year)18 Aug 2026via CNBC Awaaz.

Entry₹750Inferred

Target₹840

Stop lossNot given

CMP₹765.752d ago

Active+2.10%+9.70%upside left 12 mo left

Follow Citigroup for new calls(100% target hit, 20 closed calls)Get alerts Watch AKUMS for new buy/sell callsGet alerts See 2 other Long-term calls on AKUMS

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:47 am IST

11 supporting3 neutral0 opposing

Supports the BUY call (11)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 3d ago

Akums Drugs: Citi hikes target to Rs 860, sees 15% upside on CDMO strength

NewsGoogle News·18 Aug · 3w ago

Akums Drugs Q1FY27 net profit surges 56%; concall flags API turnaround

NewsGoogle News·13 Aug · 3w ago

Earnings Beat: Akums Drugs and Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

NewsGoogle News·12 Aug · 4w ago

Akums Drugs Target Price Hiked to Rs 850 by ICICI Securities

NewsGoogle News·11 Aug · 4w ago

Neutral / worth noting (3)

Un-audited Financial Results for the Quarter ended 30th June, 2026

BSE · Board Meeting·8 Aug · 4w ago

Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·8 Aug · 4w ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.